LAMP5 antibodies are immunological reagents designed to detect or modulate LAMP5, a member of the lysosome-associated membrane protein family. Unlike other LAMP proteins, LAMP5 (also termed BAD-LAMP) exhibits restricted expression in post-natal neurons and non-activated pDCs . Its role spans immune signaling regulation, lysosomal stability, and cancer progression, making it a target for both research and therapeutic antibodies .
MLL-rearranged Leukemia:
LAMP5 is overexpressed in mixed-lineage leukemia-rearranged (MLL-r) acute leukemia. An antibody-drug conjugate (ADC) targeting surface LAMP5 significantly reduced leukemia cell viability (in vitro IC50: 0.1–1 nM) .
Multiple Myeloma (MM):
LAMP5 expression correlates with disease progression (MGUS → MM) and poor prognosis. siRNA-mediated LAMP5 knockdown in MM cell lines (RPMI-8226, AMO-1) increased apoptosis by 30–40% (p < 0.01) via Bax/Bcl-2 modulation and p38 activation .
LAMP5 interacts with ANXA7 to stabilize lysosomal acidity, promote autophagy, and inhibit apoptosis. Overexpression of LAMP5 rescued lysosomal dysfunction in OGD/R-treated neurons, highlighting its neuroprotective potential .
In pDCs, LAMP5 regulates TLR9 trafficking from interferon-signaling endosomes (IRF-SE) to pro-inflammatory endosomes (PI-SE), balancing IFN-1 and NF-κB responses .
| Application | Findings | Source |
|---|---|---|
| Antibody-Drug Conjugate | Reduced MLL-r leukemia cell viability by 70–80% (p < 0.001) | |
| Diagnostic Marker | High LAMP5 expression in MM bone marrow predicts poor survival (HR: 2.1) |
KEGG: pon:100173676
UniGene: Pab.2703
LAMP5, also known as BAD-LAMP (Brain And Dendritic cell-associated LAMP-like molecule) and C20orf103, is a member of the LAMP family with more restricted expression patterns than other family members. Unlike typical lysosomal proteins, LAMP5 is primarily expressed in post-natal neurons and non-activated plasmacytoid dendritic cells. In neurons, LAMP5 is localized to intracellular vesicles distributed in specific microdomains along neurites and may play a role in endocytosis . LAMP5 is a mammalian ortholog of the C. elegans protein UNC-46, which functions as a sorting factor to localize the vesicular GABA transporter UNC-47 to synaptic vesicles . This connection to GABAergic neurotransmission makes LAMP5 particularly significant for neurological research, especially in studying inhibitory synaptic function.
Several LAMP5 antibodies are available for research purposes, including monoclonal antibodies like the 34.2 clone and recombinant antibodies like 82992-2-RR. The monoclonal antibody 34.2 recognizes human LAMP5 and has been tested for immunohistochemistry of formalin-fixed paraffin-embedded tissue and western blot analysis . The recombinant antibody 82992-2-RR shows reactivity with both human and mouse samples and can be used for Western Blot (WB), Immunofluorescence (IF/ICC), Flow Cytometry (FC), and ELISA applications . The choice between these antibodies depends on the specific application, species being studied, and detection method employed.
Antibody specificity validation is crucial due to potential discrepancies in staining patterns. For example, the pattern of LAMP5 immunoreactivity based on the m34.2 antibody was found to be partially contradictory to previous results obtained with a polyclonal rabbit serum . Proper validation can include:
Using LAMP5-deficient mice or knockout models as negative controls
Confirming specificity through Western blot analyses showing dose-dependent reduction in heterozygotes
Performing immunofluorescence analyses on tissues known to express or lack LAMP5
Comparing protein detection with mRNA expression patterns
This comprehensive validation approach ensures that observed signals are specific to LAMP5 rather than cross-reactivity with other proteins .
The optimal dilution of LAMP5 antibodies varies by application type and specific antibody. For the 82992-2-RR antibody, the following dilutions are recommended:
| Application | Recommended Dilution |
|---|---|
| Western Blot (WB) | 1:5000-1:50000 |
| Immunofluorescence (IF)/ICC | 1:500-1:2000 |
| Flow Cytometry (FC) (INTRA) | 0.25 μg per 10^6 cells in 100 μl suspension |
It is important to note that optimal dilutions may be sample-dependent, and it is recommended that researchers titrate the reagent in each testing system to obtain optimal results . For the monoclonal antibody 34.2, it can be used at concentrations less than or equal to 1 μg/mL for immunohistochemistry and less than or equal to 5 μg/mL for western blot analysis .
For immunohistochemistry, optimal results have been achieved using formalin-fixed paraffin-embedded tissue with high or low pH antigen retrieval methods . For in situ hybridization, 15 μm cryostat sections have been successfully used, while for immunohistochemistry, 50 μm floating sections processed with primary antibodies against LAMP5 (mAb 34.2, rat IgG, 1:400) followed by appropriate secondary antibodies have yielded good results .
For electron microscopy immunolabeling, a more specialized protocol is required: animals should be perfused with 3% PFA and 0.2% glutaraldehyde, followed by incubation of 50 μm vibratome sections with rat mAb34.2 and then with anti-rat IgG conjugated to ultrasmall nanogold particles. A silver enhancement step is necessary before processing for transmission electron microscopy .
LAMP5 antibodies require proper storage conditions to maintain their efficacy. The 82992-2-RR antibody should be stored at -20°C, where it remains stable for one year after shipment. The storage buffer consists of PBS with 0.02% sodium azide and 50% glycerol at pH 7.3 . Aliquoting is generally unnecessary for -20°C storage, though some preparations may contain 0.1% BSA for stability . For optimal performance, avoid repeated freeze-thaw cycles and protect from light, especially for fluorophore-conjugated antibodies.
This discrepancy can be explained by the synaptic localization of LAMP5 protein. For example, while LAMP5 mRNA is detected in striatal neurons, the protein is found in their main output structures (globus pallidus/ventral pallidum and substantia nigra pars reticulata), indicating that the protein is transported to the synaptic terminals . Researchers should be aware of this trafficking phenomenon when designing experiments and interpreting results.
When performing colocalization studies with LAMP5, several controls should be included:
Negative controls using LAMP5-deficient tissue to confirm antibody specificity
Single-antibody controls to assess potential channel bleed-through in fluorescence microscopy
Quantitative colocalization analysis using tools like the JacoP plugin on ImageJ
Parallel experiments with markers of different subcellular compartments to confirm localization specificity
For example, when studying colocalization of LAMP5 with GAD65 or VGAT, automated image analysis using the JacoP plugin on ImageJ was performed on multiple images taken from different sections across experiments . This quantitative approach provides robust statistical support for colocalization claims.
When faced with contradictory findings between different LAMP5 antibodies, researchers should:
Directly compare antibodies in side-by-side experiments using identical samples and protocols
Validate each antibody using genetic models (knockout or knockdown)
Cross-validate with orthogonal methods (e.g., RNA-Seq, mass spectrometry)
Consider epitope accessibility issues that might affect antibody binding
For example, the pattern of LAMP5 immunoreactivity observed with the m34.2 antibody was partially contradictory to previous results obtained with a polyclonal rabbit serum. Researchers resolved this by generating LAMP5-deficient mice and confirming antibody specificity through Western blot analyses and immunofluorescence studies .
LAMP5 antibodies are valuable tools for studying GABAergic synaptic transmission because LAMP5 is expressed in subpopulations of GABAergic neurons and co-localizes with the vesicular GABA transporter (VGAT) in synaptic vesicles. Immunofluorescence studies in the globus pallidus and the external plexiform layer of the olfactory bulb have shown that expression of VGAT largely overlaps with LAMP5, with quantitative evaluation demonstrating that 76.8-87.1% of all LAMP5-positive punctae co-label for VGAT .
Researchers can use LAMP5 antibodies to:
Identify specific subpopulations of GABAergic neurons
Study the trafficking and localization of synaptic vesicle components
Investigate the molecular machinery involved in inhibitory neurotransmission
Examine the role of LAMP5 in synaptic vesicle recycling and neurotransmitter release
Synaptic vesicle immunoisolation followed by Western blotting has confirmed the presence of LAMP5 in VGAT-positive vesicle fractions, making this a powerful approach for studying the molecular composition of inhibitory synaptic vesicles .
The relationship between LAMP5 and VGAT (vesicular GABA transporter) is complex and informs experimental approaches. LAMP5 is a mammalian ortholog of the C. elegans protein UNC-46, which functions as a sorting factor for the vesicular GABA transporter UNC-47 . This evolutionary relationship suggested a potential role for LAMP5 in trafficking VGAT to synaptic vesicles.
These findings should inform experimental design by:
Focusing on potential modulatory (rather than essential) roles of LAMP5 in GABAergic transmission
Investigating LAMP5 function in the specific subpopulations where it is expressed
Exploring potential compensatory mechanisms in LAMP5-deficient models
Recent research suggests that LAMP5 may be one of the key genes in the development of Multiple Myeloma (MM) as well as its recurrence . LAMP5 antibodies can therefore be valuable tools for multiple myeloma research in several ways:
Biomarker development: LAMP5 could serve as a biomarker for disease progression or recurrence, with antibody-based detection methods playing a key role in clinical applications.
Mechanistic studies: Antibodies can help elucidate the molecular mechanisms by which LAMP5 contributes to MM pathogenesis, potentially identifying new therapeutic targets.
Patient stratification: Expression levels of LAMP5 detected by antibody-based methods might help stratify patients into risk groups, informing treatment decisions.
Therapeutic development: If LAMP5 proves to be functionally important in MM progression, antibody-drug conjugates targeting LAMP5 could be developed as potential therapeutics.
When designing MM-related experiments with LAMP5 antibodies, researchers should consider using multiple myeloma cell lines and patient samples, comparing LAMP5 expression with established MM markers, and correlating expression with clinical outcomes.
Emerging technologies that could enhance LAMP5 antibody applications include multiplexed immunofluorescence, mass cytometry, super-resolution microscopy, and antibody engineering. The availability of conjugation-ready formats like 82992-2-PBS makes LAMP5 antibodies ideal for use in multiplex assays requiring matched pairs, mass cytometry, and multiplex imaging applications . These advanced approaches will allow researchers to study LAMP5 in previously inaccessible contexts, potentially revealing new insights into its biology and pathological roles.
Computational approaches can improve LAMP5 antibody research through automated image analysis, machine learning for pattern recognition, and integrative multi-omics analyses. When studying LAMP5 colocalization with other markers, automated image analysis using tools like the JacoP plugin on ImageJ has already proven valuable . Extending these computational approaches could help resolve the complex patterns of LAMP5 expression and trafficking, particularly given the discrepancies between mRNA and protein localization.